Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Launch of CSR programme

13 Mar 2012 07:00

RNS Number : 2001Z
Cello Group plc
13 March 2012
 



13 March 2012

 

Cello Group plc

 

Launch of CSR programme

 

Cello Group plc (AIM:CLL, 'Cello', or 'the Group'), the insight and strategic marketing group, has today launched its new Corporate Social Responsibility programme 'Talking Taboos'. 

 

Talking Taboos is a campaigning brand that aims to directly tackle health and social issues using Cello's experience and resources in the healthcare space. It will focus on areas where embarrassment, fear or ignorance prevents sufferers from seeking help.

 

For 2012, Talking Taboos will be addressing teen mental health, specifically self-harm, through an extensive research project with the teen charity YoungMinds. The research will examine the context in which teenagers find themselves when actively self-harming, and will attempt to inform parents, teachers, peers and health professionals how best to identify and support at-risk and self-harming teens.

Each Cello Group company will utilise its expertise in methodology or market sector to contribute to a 'whole community' view that will help carers and sufferers by providing context, exploding myths and challenging prevailing attitudes to self-harm. The programme is being led by Vincent Nolan, Group Chairman of Cello Research and Consulting, and the Group is planning to expand this initiative in the future to assist organisations which address a range of health related issues.

Mark Scott, Cello Group CEO, said:

 

"Talking Taboos is a great opportunity for us to support a worthwhile cause in the best way we know how - through our market leading research and our wealth of experience in working with health issues.

 

"It is also an ideal way for our companies to demonstrate their abilities and talents and work across the group to deliver a comprehensive project that should help change the way that self-harm is perceived and handled."

 

 

Enquiries:

 

Cello Group plc (www.cellogroup.com)

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Vincent Nolan, Group Chairman - Cello Research and Consulting

020 7655 9900

Cenkos

Bobbie Hilliam

020 7397 8900

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.com)

 

Cello is an insight and strategic marketing group.

 

The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenues in excess of £130m, annualised gross profit in excess of £65m and employs over 700 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUUWWUPPGMP
Date   Source Headline
11th Jan 20064:35 pmRNSNotifiable Interest
11th Jan 20067:00 amRNSPre Close Trading Statement
3rd Jan 20063:44 pmRNSHolding(s) in Company
19th Dec 20057:17 amRNSAcquisition
16th Dec 20051:57 pmRNSAdditional Listing
25th Nov 200512:53 pmRNSAcquisition
20th Oct 20058:00 amRNSInvestor Presentation
14th Oct 20058:00 amRNSChange of Adviser
3rd Oct 20057:00 amRNSOMP Services
27th Sep 20057:02 amRNSInterim Results
2nd Sep 200511:41 amRNSNotice of Results
1st Aug 20057:00 amRNSAcquisition
18th Jul 20057:00 amRNSAcquisition
14th Jul 20059:14 amRNSHolding(s) in Company
11th Jul 20057:00 amRNSPre Close Trading Statement
4th Jul 20055:44 pmRNSHolding(s) in Company
1st Jul 20057:00 amRNSAcquisition
7th Jun 20052:46 pmRNSDirector Share Option Award
6th Jun 20054:43 pmRNSAcquisition Agreement
23rd May 200512:30 pmRNSAGM Statement
4th May 20058:41 amRNSBoard Appointment
25th Apr 20057:00 amRNSBoard Appointment
14th Mar 20057:01 amRNSFinal Results
10th Mar 20054:18 pmRNSHolding(s) in Company
1st Feb 200512:00 pmRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.